Objectives: There is a dearth of information on the experience of pain in persons living with human immunodeficiency virus (HIV) and cooccurring psychologic and substance use problems. This study examined the prevalence and correlates of pain in 162 HIVpositive persons diagnosed with mood and/or anxiety disorders and substance use disorders.
P ain is recognized as a source of considerable distress and disability among persons living with human immunodeficiency virus (HIV). [1] [2] [3] [4] [5] [6] [7] Pain in the context of HIV may derive from multiple sources, 3 including the effects of HIV disease on the nervous system, immune suppression, iatrogenic treatment effects (eg, antiretroviral medications), various disorders associated with HIV, 8 and factors unrelated to HIV (eg, preexisting conditions) or its treatment. 8, 9 In convenience samples of HIV-infected persons, the prevalence of pain has been estimated at between 25% and 80%. 1, 4, 10, 11 In the HIV Cost and Services Utilization Study (HCSUS), the first nationally representative sample of HIV-positive persons in the United States, our prior research indicated that 67% reported experiencing pain during the previous month. 12 Recent models have conceptualized pain as a multidimensional construct incorporating biologic, psychologic, and social aspects. 13 Consistent with this biopsychosocial model, investigators have begun to focus on the impact of coexisting psychologic and substance use disorders on the experience of pain among HIV-infected persons. 2, 3 Mood and anxiety disorders are the most common Axis I psychologic disorders among HIV-positive persons. In the HCSUS, approximately 48% screened positive for a mood or anxiety disorder, and roughly 12% screened positive for substance dependence. 14 In HIV, the presence of pain has been strongly linked with mood and anxiety disorders. One study found that HIV-positive individuals with posttraumatic stress disorder (PTSD) reported greater pain intensity and pain-related interference than those without PTSD. 15 In the HCSUS, we previously found that pain showed strong concurrent associations with panic disorder, major depression, and PTSD. 16 Longitudinal analyses however, showed that increasing pain over a time was associated with the presence of panic disorder, but not with major depression or PTSD.
The literature on the relationship between substance abuse and pain in HIV is more mixed. Although research in convenience samples indicates that HIV-positive individuals who are injection drug users (IDUs) report increased pain compared with non-IDUs, 7, 9, 17, 18 at least 2 studies did not find differences in pain report between these groups. 1, 19 In the HCSUS, our earlier work indicated that screening positive for drug dependence in relation to a broad range of substances (not just IDU), was associated with increased pain. 6 In addition, drug dependence was predictive of increased pain over time, even after controlling for prior pain. Of note, in the studies which found no differences in pain report among IDUs versus non-IDUs approximately 70% met criteria for acquired immunodeficiency syndrome (AIDS). In contrast, in the HCSUS, only about 36% met AIDS criteria. Thus, it is possible that at more advanced stages of HIV disease, differences in pain report based on substance abuse history may be less prominent.
Despite the high prevalence of comorbid psychologic and substance use disorders in HIV, there is a paucity of research on the experience of pain in HIV-positive individuals with both comorbid substance use disorders and psychologic disorders. Such ''triply diagnosed'' HIVpositive persons are reported to have poorer health outcomes, lower medication adherence rates, and lower treatment and retention rates compared with the general HIV population. 20, 21 To the authors' knowledge no prior work has focused on identifying the correlates of pain among triply diagnosed HIV-positive persons. Thus, the purpose of this study was to determine the prevalence of pain in a sample of triply diagnosed HIV-positive persons and to identify key sociodemographic and clinical characteristics associated with pain in these individuals. In contrast to previous work that relied on diagnostic screeners, the current sample was determined to meet full criteria for both psychologic and substance use disorders using the gold standard for clinical diagnostic interviews [ie, The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorder-IV (DSM-IV) (SCID) 22, 23 (described fully below).
MATERIALS AND METHODS

Participants
This study analyzed data from a cohort of 162 HIVinfected patients with current DSM-IV psychologic and substance use disorders. These data were derived from a larger study (described below). The 162 participants were recruited from May 2000 to July 2003, at the CORE center, Chicago; a public urban ambulatory care facility serving mostly socioeconomically disadvantaged HIV-infected patients. The current sample was originally recruited as part of the larger HIV/AIDS Treatment Adherence, Health Outcomes, and Cost Study, a multiyear cooperative agreement involving 8 study sites and jointly funded by agencies within the Substance Abuse and Mental Health Services Administration, the Health Resources and Services Administration, and National Institutes of Health. This multisite study examined the effectiveness of integrated care for HIV-infected persons with cooccurring psychologic and substance abuse disorders. 24 All participants included in this study signed informed consent forms, and the study was approved by the hospital's institutional review board. Demographic information for the 162 patients in this study is displayed in Table 1 .
Procedure
A flow chart illustrating participant enrollment for the current sample is shown in Figure 1 . In brief, from May 2000 to August 2002, 1176 adult HIV patients were screened using items from standardized instruments (Composite International Diagnostic Interview, 25 SCID, 22 Alcohol Use Disorders Identification Test, 26 and Clinical Diagnostic Questionnaire 27 ). Only those who screened positive, that is reported symptoms associated with psychologic and substance use disorders were eligible for diagnostic interview using selected diagnostic modules of the SCID. Trained interviewers administered the initial screener, conducted the diagnostic interview, and collected additional patient self-report data. The full baseline assessment was conducted over 2 sessions. The SCID interview was given in session 1 to determine diagnostic study eligibility. Patients who met diagnostic eligibility were then scheduled for session 2. The session 2 assessment included sociodemographics, physical and mental health functioning, and substance use severity. Only those measures relevant to this study are discussed below. Each session averaged 1.5 hours in length. Patients were paid $20 for these assessments.
Measures
Addiction Severity Index (ASI-Lite) 28 assessed alcohol and drug use severity. The ASI is a structured interview instrument with good psychometric properties that measures alcohol and illicit drug-related behaviors and quantifies the status of use over time. 29 Discriminant and concurrent validity of the ASI has been established in previous samples. [30] [31] [32] The ASI provides summary scores for each domain. For this study, summary scores were used for the following 2 domains: alcohol use, illicit drug use. For each domain the ASI provides a severity rating based on subjective and objective data (scores range from 0 to 9; larger values indicate greater severity), and a mathematically derived composite score of current behavior (ie, past 30 d). Information on the frequency of drug use (all drugs) and alcohol use in the past 30 days collected in the ASI was used to derive the average number of days in the past month that patients used drugs and alcohol. SCID 22, 23 was used to diagnose psychologic and substance use disorders. The SCID is viewed as the gold standard for clinical diagnosis in adults. 22, 23 Test-retest reliabilities of reliability coefficients for schizophrenia, mood, alcohol, and substance abuse disorder diagnoses exceed 60. 23, 33 On the basis of the SCID, participants were classified into 2 categories: mood disorders (major depres-sion, dysthymia, bipolar disorder) and anxiety disorders (generalized anxiety disorder, panic disorder/agoraphobia, PTSD). Substance use diagnostic categories included alcohol abuse/dependence and nonalcohol substance abuse/ dependence. Short-form 36 (SF-36) [34] [35] [36] bodily pain (BP) scale was used to assess pain. The SF-36 is an extensively used and psychometrically sound survey instrument. Normative data for the SF-36 in the general US population are available. 37 The BP scale of the SF-36 consists of 2 items: (1) How much BP have you had during the past 4 weeks? Responses range from ''none'' = 1 to ''very severe'' = 6; (2) ''During the past 4 weeks, how much did pain interfere with your normal work (including work outside the house and housework)?'' Responses range from ''Not at all'' = 1, to ''extremely'' = 5. Raw scores for the BP items are linearly transformed to a 0 to 100 scale. Lower scores on the BP scale indicate greater pain.
CD4 + (T-helper lymphocyte) cell counts were abstracted from the patients' medical charts. Absolute values of CD4 cell counts were available for all but 6 participants. For 3 of these participants, self-reported CD4 values, assessed at the baseline interview were included. Prior work has showed strong correlations between self-reported and actual CD4 cell counts, supporting the validity and reliability of self-report data. 38, 39 CD4 cell counts were dichotomized into 2 categories: counts above and counts below 200 (200 Â 10 3 cells/mm 3 ). CD4 cell counts below 200 are sufficient for diagnosis of AIDS, even in the absence of AIDS-defining illnesses. 40 The 3 participants without selfreport or actual CD4 cell count data were excluded from analyses involving CD4 data.
Demographic and clinical characteristics were assessed during the baseline interviews. Information on age, sex, race, education, insurance status, HIV transmission, and use of HIV medications was gathered. Adherence to HIV medication use in the past 3 days was assessed and the extent of adherence was categorized according to algorithms established for this study using a 1 to 6 scale ranging from ''not at all adherent'' to ''completely adherent.''
Statistical Analysis
One sample t tests were used to compare BP scores in the current sample with scores reported for the general US population 37 and a national sample of HIV-positive persons using data drawn from the HCSUS 16, 41 (for information on the HCSUS see Ref. 42 ). The HCSUS did not conduct formal diagnostic interviews; instead brief screeners were used to screen for mental health problems. Scores in the present sample were compared with HCSUS participants who screened negative for anxiety disorders, depressive disorders, or substance dependence in the past year.
To examine correlates of pain, bivariate analyses were used to quantify the relationships among the variables before multivariate modeling. Bivariate analyses involved independent t tests to test for differences in BP scores based on sex (male vs. female), race (African American vs. non-African American), CD4 counts (above 200 vs. below 200), use of HIV medications (yes/no) and presence of psychologic (anxiety; depression) and substance use (alcohol; nonalcohol) disorders. In addition, a 1-way analysis of variance tested for differences in BP scores based on educational level (below high school diploma; high school diploma; some college/associate's degree; college degree and higher), and Pearson product moment correlation coefficients were generated to characterize the association between BP scores and age (years), ASI drug and alcohol severity scores, average days of drug use (all drugs), alcohol use in the past 30 days, and HIV medication adherence. Significant bivariate correlates of BP scores were then subjected to multivariate analysis. Multiple linear regression was used to evaluate the relationship between the independent variable (BP scores), and the dependent variables identified in the bivariate analyses. All dependent variables were entered simultaneously into the multiple regression model. A standard probability level of 0.05 was used to evaluate the results.
RESULTS
Comparison of Pain Scores With Normative Data
The mean BP score in the current sample was 55.1 (SD = 28.6). The mean score for the US general population is 75.2 (SD = 23.7). Pain scores in the present sample were significantly lower than normative values indicating higher levels of pain (t = À 8.92, P<0.001). The current sample also scored significantly lower than HCSUS participants who did not screen positive for anxiety disorders, depressive disorders, or substance dependence in the past year (mean = 76.7; SD = 24.7) (t = À 9.61, P<0.001). Bodily pain scores were inversely associated with age (r = À 0.21, P<0.01), indicating that younger age was associated with less pain. Average days of drug use (all drugs) in the past 30 days was positively associated with BP (r = À 0.17, P<0.05). Bodily pain scores were not associated with sex, race, education, use of HIV medications, presence of anxiety disorder, ASI drug or alcohol severity scores, average days of alcohol use in the past 30 days, presence of alcohol or nonalcohol substance use disorders, or adherence to HIV medications.
Bivariate Correlates of Pain Scores
Multivariate Analyses of Pain Scores
On the basis of the bivariate findings, the following dependent variables were examined in multivariate analyses of pain scores: age, CD4 counts, presence of mood disorder, and average days of drug use. Results of the multiple linear regression analysis are shown in Table 2 . As displayed in the table, the b coefficients for the following independent variables were significantly different from zero: age, CD4 counts, and presence of mood disorder. The b coefficient for average days of drug use did not differ significantly from zero. Presence of mood disorder accounted for the largest share of unique variance in BP scores (4%), followed by age (3% of unique variance), and CD4 counts (2% of unique variance). The complete model including all predictors explained 12% (10% adjusted) of the variance in pain scores.
DISCUSSION
This sample HIV-positive persons with diagnosed comorbid psychologic and substance use disorders reported high levels of BP that were substantially greater than the general US population. Bodily pain scores were on average, 20 points lower (indicating more pain) in the current sample compared with normative values and scores among HIVpositive persons who screened negative for anxiety disorders, depressive disorders, or substance dependence. This difference greatly exceeds the 5 point difference in SF-36 scores generally considered to be clinically significant. 37 Bivariate analyses indicated that the presence of mood disorder, low CD4 cell counts (below 200), older age, and more days of drug use (all drugs) in the past month were associated with increased pain. All of these correlates except for days of drug use were significantly associated with pain in multivariate analyses ( Table 2 ). Of note, the presence of mood disorder explained the largest share of unique variance in BP scores, followed by age and CD4 counts. Pain scores were on average were nearly 12 points lower among persons with a current mood disorder compared with those without mood disorder-a difference that is a clinically significant. These findings are consistent with prior work indicating a strong relationship between pain and depressive symptoms in HIV-positive persons. 5, [43] [44] [45] In contrast, the current results are somewhat at odds with our previous research in the HCSUS, which indicated that increasing pain over time was associated with panic disorder but not major depression or PTSD. 16 In fact, the present study did not find a significant relationship between presence of anxiety disorder and pain. A possible explanation for these divergent findings is that there were many more HIV-positive persons in the current sample diagnosed with a mood disorder (44%) than an anxiety disorder (>5%). In contrast, the prevalence of major depression, panic disorder, and PTSD were all fairly similar in the HCSUS and ranged between 5% and 9%. 16 The present findings indicate that the presence of clinical depression may be a stronger marker of concurrent pain than clinical anxiety among HIV-positive persons with cooccurring psychologic and substance use disorders.
As discussed above, multivariate analyses also revealed a significant association between increased pain and lower CD4 counts. Pain scores were on average almost 10 points lower among those with low CD4 counts (<200) relative to those with high CD4 counts, a clinically b indicates standardized regression coefficient; model R 2 , coefficient of determination (goodness of fit) for overall regression model after entry of each independent variable; sr 2 (unique), unique contribution of an independent variable to R 2 in the total set of independent variables. meaningful difference. These findings concur with prior studies supporting an association between increased pain and more advanced HIV disease. 8, 12, 43, [45] [46] [47] Similarly, we previously reported that in the HCSUS, drug dependence was directly related to increased HIV illness burden (ie, more advanced HIV clinical stage and presence of wasting syndrome) which in turn predicted greater pain over time. 6 However, it should be noted that some studies have not found a relationship between more advanced HIV disease and increased pain. 11, 48 Differences in the assessment of pain and/or the extent of HIV disease progression across samples may account for these discrepant results.
The finding that older age was associated with increased pain in multivariate analyses is consistent with findings in the general population. 36 In contrast, we found no association between age and reported pain in our prior research in the HCSUS. 12 The divergence between these findings is somewhat surprising given that the mean age of the current sample and the HCSUS sample are quite similar (ie, 39.7 and 38.8 y, respectively). However, the age range in the HCSUS sample was much broader (ie, 18 to 77 y) than the current sample (ie, 24 to 60 y). Reasons for the different age-based findings in the 2 samples are unclear, although it should be noted that the age-related results in both samples held after accounting for HIV disease status.
Perhaps the most unexpected finding in the current sample was the lack of association between drug or alcohol use and reported pain. Although the bivariate analyses revealed that more days of drug use over the past 30 days was associated with greater pain, this relationship was not significant in the multivariate analyses. Pain was not correlated with drug or alcohol severity scores, days of alcohol use in the past month, or with the presence of alcohol or nonalcohol substance use disorders. These findings are inconsistent with our previous research in the HCSUS which found an association between use of a broad range of illicit substances, and increased pain. 6 In contrast, the current results agree with at least 2 prior studies indicating no differences in pain report between IDUs and non-IDUs. 1, 19 It is possible that in the current sample, there was insufficient variation in the extent of drug/alcohol use which may have attenuated any potential association with pain.
In the current sample, pain scores did not vary based on sex, race, education, or use of HIV medications (yes/no). These findings diverge somewhat from prior reports. In the HCSUS, we found that BP scores were lower, indicating more pain, among IV-drug using women (compared with men who have sex with men), the unemployed, and the less educated. 12 In contrast, BP scores were higher (indicating less pain) among African Americans relative to whites. 12 An earlier study in a convenience sample of HIV-positive persons found that not only did women report more pain than men, nonwhites reported more pain compared with whites 1 It is possible that variations in pain assessment and/or in sample characteristics may account for these discrepant findings. Additional investigations on racial/ ethnic and sex differences in pain among HIV-positive persons are warranted.
Although this study is the first to the authors' knowledge to specifically examine the prevalence and correlates of pain in HIV-positive persons with comorbid psychologic and substance use disorders, limitations should be noted. First, the high patient volume during clinic hours made it difficult to locate, recruit and screen all eligible study participants. Thus, of the 1412 eligible participants contacted, 78% were screened (Fig. 1) . Second, the multistep enrollment process impacted study attrition rates. For example, after participants were screened eligible, the baseline assessment was administered over 2 sessions; both sessions were to be administered within a 1-month time frame. As a result, 16% (62/374) of the participants that were eligible for SCID interview missed their initial baseline interview and 6% missed session 2 of their baseline assessment.
In sum, this study found that HIV-positive persons with comorbid psychologic and substance use disorders reported more pain than the US general population. The differences in reported pain were substantial and clinically meaningful. The key correlates of increased pain in the current sample were the presence of mood disorder, older age, and CD4 counts below 200. Of note, the presence of mood disorder accounted for the largest share of unique variance associated with pain, suggesting that mood disorders may be a key marker for pain among triply diagnosed HIV-positive individuals. The current findings support the need for an enhanced focus on the identification and treatment of pain among HIV-positive persons. As the present investigation and others 1, 5, 11, 12, 18, 19, [46] [47] [48] have noted, pain remains a considerable problem in HIV despite advances in treatment approaches. Moreover, several reports suggest that pain is undertreated in HIV-positive persons, 1, 4, 10, 11, 45, 49 and this undertreatment of pain is especially prominent among women, the less educated, and IDUs. 49 Future research should examine the extent to which pain among HIV-positive persons with cooccurring psychologic and substance use disorders is adequately addressed, particularly as the current analysis indicates that this population is especially vulnerable to the experience of pain.
